Inscription Capital’s Takeda Pharmaceutical TAK Stock Holding History

Inscription Capital’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$344K	Sell	21,480 -531	-2%	-$8.79K	0.03%	504
2026 Q1	$408K	Buy	22,011 +778	+4%	+$13.7K	0.04%	414
2025 Q4	$331K	Buy	21,233 +17	+0.1%	+$243	0.03%	459
2025 Q3	$311K	Buy	21,216 +2,557	+14%	+$38K	0.03%	479
2025 Q2	$288K	Sell	18,659 -3,160	-14%	-$46.7K	0.04%	371
2025 Q1	$303K	Buy	+21,819	New	+$306K	0.05%	246
2024 Q3	$322K	Buy	22,663 +94	+0.4%	+$1.33K	0.05%	257
2024 Q2	$292K	Buy	22,569 +750	+3%	+$9.93K	0.05%	251
2024 Q1	$303K	Buy	+21,819	New	+$317K	0.05%	246
2019 Q2	–	Sell	-14,920	Closed	-$304K	–	217
2019 Q1	$304K	Buy	+14,920	New	+$300K	0.16%	88

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Inscription Capital's TAK Position: Q2 2026 in Review

Inscription Capital reduced its Takeda Pharmaceutical (TAK) stake by 2.4% in Q2 2026, selling an estimated $8.79K and leaving 21,480 shares worth $344K. The position accounts for 0.03% of the portfolio, ranked #504.

Inscription Capital first reported a position in TAK in Q1 2019 and has held it in 10 quarters since. The position peaked at $408K in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Inscription Capital held 21,480 shares of Takeda Pharmaceutical worth $344K as of Q2 2026.
Inscription Capital sold 531 Takeda Pharmaceutical shares in Q2 2026, an estimated $8.79K.
Takeda Pharmaceutical made up 0.03% of Inscription Capital's portfolio in Q2 2026, its #504 holding.
Inscription Capital first reported a position in Takeda Pharmaceutical in Q1 2019 and has held it in 10 quarters since.
Inscription Capital's Takeda Pharmaceutical position peaked at $408K in Q1 2026.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.